Do antidepressants reduce the burden imposed by depression on employers?

CNS Drugs

Volumn 19, Issue 3, 2005, Pages 253-264

  Greener, Mark J ^a   Guest, Julian F ^a  

^a CATALYST Health Economics Consultants   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINEPTINE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENTEEISM; ALERTNESS; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEPRESSION; DRUG EFFICACY; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PRIORITY JOURNAL; PRODUCTIVITY; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SOCIAL STATUS; SYSTEMATIC REVIEW;

ABSENTEEISM; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; EFFICIENCY; EMPLOYMENT; HUMANS; RECURRENCE; TREATMENT OUTCOME;

EID: 16244377455     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519030-00006     Document Type: Review

References (59)

1. Styron W. Darkness visible: a memoir of madness. London: Jonathan Cape, 1991: 33-4
2. Wells KB, Stuart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262 (7): 914-9
3. Goetzel RZ, Ozminkowski RJ, Sederer LI, et al. The business case for quality mental health services: why employers should care about the mental health and well-being of their employees. J Occup Environ Med 2002; 44 (4): 320-30
4. Vernarec E. Depression in the workforce: seeing the cost in a fuller light. Bus Health 2000; 18 (4): 48, 52, 55
5. Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff 1999; 18 (5): 163-71
6. Riotto M. Depression in the workplace: negative effects, perspective on drug costs and benefit solutions. Benefits Q 2001; 17 (2): 37-48
7. Allgulander C, Kasper S. Coping with somatic comorbidities: striving for complete recovery. Psychopharmacol Bull 2002; 36 Suppl. 2: 103-11
8. Russell JM, Patterson J, Baker AM. Depression in the workplace. Dis Manage Health Outcomes 1998; 4 (3): 135-42
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994
10. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002; 53: 849-57
11. Guze BH. Selective serotonin reuptake inhibitors assessment for formulary inclusion. Pharmacoeconomics 1996; 9 (5): 430-42
12. Williams RA, Strasser PB. Depression in the workplace. AAOHN J 1999; 47 (11): 526-39
13. Brodsky CM. Depression and chronic fatigue in the workplace: workers' compensation and occupational issues. Prim Care 1991; 8 (2): 381-96
14. Druss BG, Schlesinger M, Allen HM, et al. 2001. Depressive symptoms, satisfaction with health care and 2-year outcomes in an employed population. Am J Psychiatry 2001; 158 (8): 731-4
15. Zhang M, Rost KM, Fortney JC. Earnings changes for depressed individuals treated by mental health specialists. Am J Psychiatry 1999; 156 (1): 108-14
16. Lepine J-P, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12 (1): 19-29
17. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002; 63: 963-7
18. Bromberger JT. A psychosocial understanding of depression in women: for the primary care physician. J Am Med Womens Assoc 2004; 59 (3): 198-206
19. Stewart DE, Rondon M, Damiani G, et al. International psychosocial and systemic issues in women's mental health. Arch Women Ment Health 2001; 4 (1): 13-7
20. Santiago JM. The costs of treating depression. J Clin Psychiatry 1993; 54: 425-6
21. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med 1999; 61: 6-17
22. Farmer A, Redman K, Harris T, et al. The Cardiff sib-pair study: suicidal ideation in depressed and healthy subjects and their siblings. Crisis 2001; 22: 71-3
23. Lejoyeux M, Leon E, Rouillon F. Prevalence and risk factors of suicide and attempted suicide. Encephale 1994; 20: 495-503
24. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997; 154 (10): 1417-23
25. Ford DE, Cooper-Patrick L. Sleep disturbances and mood disorders: an epidemiologic perspective. Depress Anxiety 2001; 14: 3-6
26. Marlowe JF. Depression's surprising toll on worker productivity. Empl Benefits J 2002; 27 (1): 16-21
27. Ostler K, Thompson C, Kinmonth AL, et al. Influence of socio-economic deprivation on the prevalence and outcome of depression in primary care. Br J Psychiatry 2001; 178 (1): 112-7
28. Wing JK. Mental illness DHA project epidemiologically based needs assessment. London: Department of Health, 1992
29. McGuire A, Hughes D. The economic evaluation of depression. Postgrad Med J 1994; 70 Suppl. 2: S14-22
30. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54 (11): 405-17
31. McHugh M. Rationalization as a key stressor for public sector employees: an organizational case study. Occup Med 1998; 48 (2): 103-12
32. Martin JK, Blum TC, Beach SRH, et al. Subclinical depression and performance at work. Soc Psychiatry Psychiatr Epidemiol 1996; 31: 3-9
33. Beuzen JN, Ravily VF, Souetre EJ, et al. Impact of fluoxetine on work loss in depression. Int Clin Psychopharmacol 1993; 8 (4): 319-21
34. Broadhead W, Blazer D, George L, et al. Depression, disability days and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264: 2524-8
35. Selzer ML, Paluszny M, Carroll R. A comparison of depression and physical illness in men and women. Am J Psychiatry 1978; 135 (11): 1368-70
36. Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA 2003; 289: 3135-44
37. Pauly MV, Nicholson S, Xu J, et al. A general model of the impact of absenteeism on employers and employees. Health Econ 2002; 11: 221-31
38. Goldberg RJ. Depression in the workplace: economics and interventions. Behav Healthc Tomorrow 2001; 10 (6): 10-1
39. Ericsson M, Poston WSC, Linder J, et al. Depression predicts disability in long-term chronic pain patients. Disabil Rehabil 2002; 24 (6): 334-40
40. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004; 65 Suppl. 16: 27-32
41. Foley D, Ancoli-Israel S, Britz P, et al. Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res 2004; 56 (5): 497-502
42. Souetre E, Lozet H, Martin P, et al. Work loss and depression. Impact of fluoxetine. Therapie 1993; 48: 81-8
43. Souetre E, Lozet H, Cimarosti I. Predicting factors for absenteeism in patients with major depressive disorders. Eur J Epidemiol 1997; 13: 87-93
44. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000; 22: 153-62
45. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49 (10): 761-8
46. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: TCAs vs selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 17-25
47. Fairweather DB, Ashford J, Hindmarch I. Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers. Pharmacol Biochem Behav 1996; 53: 265-9
48. British National Formulary No. 48. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 2004: 195
49. Moller HJ. Are all antidepressants the same? J Clin Psychiatry 2000; 61 Suppl. 6: 24-8
50. Birnbaum HG, Cremieux PY, Greenberg PE, et al. Management of major depression in the workplace: impact on employee work loss. Dis Manage Health Outcomes 2000; 7 (3): 163-71
51. Lin E, Von Korff M, Ludman E, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry 2003; 25 (5): 303-10
52. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002; 105 (3): 164-72
53. Young AS, Klap R, Sherbourne CD, et al. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001; 58 (1): 55-61
54. Katzelnick DJ, Kobak KA, Greist JH, et al. Effect of primary care treatment of depression on service use by patients with medical expenditures. Psychiatr Serv 1997; 48 (91): 59-64
55. Zhang M, Rost KM, Fortney JC, et al. A community study of depression treatment and employment earnings. Psychiatr Serv 1999; 50 (9): 1209-13
56. Greenberg PE, Stiglin LE, Finkelstein SN, et al. Depression: a major neglected illness. J Clin Psychiatry 1993; 54 (11): 419-24
57. Kessler RC, Frank RG. The impact of psychiatric disorders on work loss days. Psychol Med 1997; 27: 861-73
58. Marcotte DE, Wilcox-Gok V, Redmon DP. The labor market effects of mental illness: the case of affective disorders. In: Salkever D, editor. The economics of disability. Amsterdam: JAI Press, 2000
59. Wang PS, Beck AL, McKenas DK, et al. Effects of efforts to increase response rates on a workplace chronic condition screening survey. Med Care 2002; 40 (9): 752-60